US Patent

US10709691 — Pharmaceutical dosage forms

Method of Use · Assigned to Recordati SA · Expires 2035-10-12 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical dosage forms for oral administration of OSILODROSTAT PHOSPHATE or its pharmaceutically acceptable salts.

USPTO Abstract

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4177`	—	osilodrostat-phosphate
`U-4177`	—	osilodrostat-phosphate
`U-2770`	—	osilodrostat-phosphate

Patent Metadata

Patent number: US10709691
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-12
Drug substance claim: No
Drug product claim: No
Assignee: Recordati SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.